Laxmi Dental Ltd

Laxmi Dental maintains a strong liquidity position with a current ratio of 3.3 and cash and equivalents of INR 610.93 million, which is well above the industry median. The company's liquidity_fpt score indicates a low liquidity risk, supported by a debt-to-equity ratio of 0.09, suggesting a conservative capital structure. Profitability metrics show a return on equity (ROE) of 15.24% and a return on assets (ROA) of 11.16%, both exceeding the industry median for medical equipment and supplies. The operating margin of 14.21% (calculated from operating income of INR 339.55 million on revenue of INR 2.39 billion) is robust, indicating efficient cost management and pricing power. The company's revenue is distributed across three segments: Laboratory Business, Aligners Business, and Other Business. The Laboratory Business is the largest contributor, with a focus on dental prosthesis and crowns. The Aligners Business, which includes clear aligners and related products, is a growing segment. The Other Business includes dental distribution and educational services. Revenue concentration is not disclosed, but the diversification across segments suggests a balanced exposure. Growth trajectory is positive, with the company's FY outlook indicating a revenue increase. The operating cash flow of INR 438.32 million and free cash flow of INR 243.13 million support reinvestment and shareholder returns. The capital expenditure of INR 160.78 million is modest, suggesting a focus on maintaining rather than expanding capacity. Risk factors are minimal, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics. The conservative capital structure and strong cash position reduce financial risk. Recent events include analyst estimates with a mean price target of INR 316.67 and a median of INR 290.00. The mean recommendation is 1.33, indicating a strong buy consensus. No recent filings or transcripts have been disclosed that would suggest material changes in the company's operations or strategy.